Perceptive Advisors buys $18,615,000 stake in Eagle Pharmaceuticals Inc (EGRX)

Eagle Pharmaceuticals Inc (EGRX) : Perceptive Advisors scooped up 112,785 additional shares in Eagle Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 300,000 shares of Eagle Pharmaceuticals Inc which is valued at $18,615,000.Eagle Pharmaceuticals Inc makes up approximately 1.36% of Perceptive Advisors’s portfolio.

Other Hedge Funds, Including , American Century Companies Inc boosted its stake in EGRX in the latest quarter, The investment management firm added 6,567 additional shares and now holds a total of 114,901 shares of Eagle Pharmaceuticals Inc which is valued at $5,393,453. Eagle Pharmaceuticals Inc makes up approx 0.01% of American Century Companies Inc’s portfolio. Strs Ohio sold out all of its stake in EGRX during the most recent quarter. The investment firm sold 6,100 shares of EGRX which is valued $286,334. Lasalle Street Capital Management added EGRX to its portfolio by purchasing 7,846 company shares during the most recent quarter which is valued at $360,210. Eagle Pharmaceuticals Inc makes up approx 0.33% of Lasalle Street Capital Management’s portfolio.

Eagle Pharmaceuticals Inc opened for trading at $62.73 and hit $63.48 on the upside on Tuesday, eventually ending the session at $62.27, with a gain of 3.94% or 2.36 points. The heightened volatility saw the trading volume jump to 11,41,800 shares. Company has a market cap of $974 M.

On the company’s financial health, Eagle Pharmaceuticals Inc reported $0.80 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $0.71. The company had revenue of $40.90 million for the quarter, compared to analysts expectations of $39.20 million. The company’s revenue was up 581.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.53 EPS.

Many Wall Street Analysts have commented on Eagle Pharmaceuticals Inc. Company shares were Reiterated by Mizuho on Aug 16, 2016 to “Neutral”, Firm has raised the Price Target to $ 65 from a previous price target of $47 .Shares were Downgraded by Mizuho on Jun 20, 2016 to ” Neutral” and Lowered the Price Target to $ 47 from a previous price target of $66 .

Eagle Pharmaceuticals Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD) an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda and Ryanodex (dantrolene for MH) and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101 EP-3102 Ryanodex EP-4104 EP-6101 EP-5101 EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Eagle Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eagle Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.